10 completed, 1 terminated, 1 unknown. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 10, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Pegylated Interferon: new trials by email Literature Review of Pegylated Interferon trials Research Report on Pegylated Interferon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B Hepalatide 2.1mg, Hepalatide 4.2mg, Hepalatide 6.3mg - Hepatitis B, Chronic | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 96 | 2021-06-18 | 2025-01-27 |
| Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B REP 2139-Ca, pegylated interferon, entecavir - Hepatitis B, Chronic | Phase 2 | Completed | Replicor Inc. | 5 | 2012-10-01 | 2019-05-08 |
| Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders CTS-1027, pegylated interferon, Ribavirin - Hepatitis C | Phase 2 | Terminated | Conatus Pharmaceuticals Inc. | 114 | 2011-01-01 | 2012-06-11 |
| Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg - Self Efficacy, Hepatitis C | Phase 2 / Phase 3 | Unknown | BioGeneric Pharma | 300 | 2010-11-01 | 2011-04-04 |
| Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders CTS-1027, Pegylated interferon, Ribavirin - Hepatitis C | Phase 2 | Completed | Conatus Pharmaceuticals Inc. | 67 | 2010-01-01 | 2012-04-16 |
| A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon - Hepatitis C, Chronic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 45 | 2009-10-23 | 2021-02-08 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection ABT-333, Placebo for ABT-333, Pegylated interferon - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 30 | 2009-03-01 | 2018-07-02 |
| Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy valopicitabine, pegylated interferon, ribavirin - Chronic Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 2005-01-01 | 2010-06-10 | |
| Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C valopicitabine, pegylated interferon - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 2004-07-01 | 2010-06-10 | |
| Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients Pegylated Interferon, Lamivudine - Chronic Hepatitis B | Phase 2 | Completed | Chinese University of Hong Kong | 30 | 2002-12-01 | 2008-10-24 |
| A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma Pegylated Interferon, Interferon-alpha2a - Multiple Myeloma | Phase 2 | Completed | Royal Marsden NHS Foundation Trust | 2001-03-01 | 2006-05-09 | |
| Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers Polyenylphosphatidylcholine (PPC), Pegylated Interferon, Ribavirin - Hepatitis C | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 207 | 2000-06-01 | 2017-01-27 |
Hepatitis C (5) · Hepatitis B, Chronic (3) · Hepatitis C, Chronic (3) · Multiple Myeloma (1)
Merck Sharp & Dohme LLC (3) · Conatus Pharmaceuticals Inc. (2) · AbbVie (prior sponsor, Abbott) (1) · BioGeneric Pharma (1) · Chinese University of Hong Kong (1) · Icahn School of Medicine at Mount Sinai (1) · Replicor Inc. (1) · Royal Marsden NHS Foundation Trust (1) · Shanghai HEP Pharmaceutical Co., Ltd. (1)
United States (6) · Puerto Rico (3) · China (2) · Egypt (1) · United Kingdom (1)
Erin Castelloe, MD (2) · Charles S Lieber, MD (1) · Daniel Cohen, MD (1) · Fusheng Wang (1) · Gamal Esmat, MD (1) · Henry LY Chan, MD (1) · Mamun Al-Mahtab, MD (1) · Mohamed Karim F Ashour, MD (1) · Ray Powles, FRCP, FRCpath (1)
2009 (1)